Inogen Achieves Best In Class 8-Year Expected Service Life Portable Oxygen Concentrators
07 August 2023 - 2:30PM
Business Wire
Inogen, Inc. (Nasdaq: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced the introduction of the Rove 6™ portable
oxygen concentrator in the United States with best in class 8-year
expected service life.
The Inogen® Rove 6™ was launched in Europe in December 2022.
Having completed the necessary regulatory processes, the expected
service life of the Rove 6 will be extended from 5 years to 8 years
for all Rove 6 devices sold worldwide. The 8 year best-in-class
expected service life has also been extended to Inogen One® G5
portable oxygen concentrators in the US.
“In capital-based business models it is critical to maximize the
value of the devices you invest in to enhance your returns. We are
excited to now be able to extend this opportunity to Inogen’s
business-to-business customers allowing them to improve the
profitability of their oxygen concentrator business and strengthen
the appeal of the non-delivery long-term oxygen therapy model,”
said Nabil Shabshab, President and Chief Executive Officer of
Inogen. “As a global market leader with a focus on delivering high
quality and innovative respiratory care solutions, Inogen is well
positioned to deliver the best portable oxygen concentrator for
business-to-business customers, with a differentiated value
proposition through a strong total cost of ownership, best-in-class
quality, best after sales services, and now the best-in-class
expected service life.”
The Inogen® Rove 6™ is a 6-setting portable oxygen concentrator
that also provides the longest battery life of any portable oxygen
concentrator currently available on the market. This device
delivers up to 1,260 mL/minute of medical grade oxygen at a weight
of only 4.8 pounds. The Inogen® Rove 6™ is available with two
battery options, including an extended battery that can support a
battery life up to 12 hours and 45 minutes.
For more information, please visit Inogen Rove 6 System.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical
technology company offering innovative respiratory products for use
in the homecare setting. Inogen supports patient respiratory care
by developing, manufacturing, and marketing innovative
best-in-class portable oxygen concentrators used to deliver
supplemental long-term oxygen therapy to patients suffering from
chronic respiratory conditions. Inogen partners with patients,
prescribers, home medical equipment providers, and distributors to
make its oxygen therapy products widely available allowing patients
the chance to remain ambulatory while managing the impact of their
disease.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, Inogen’s expected service life of
its products and the impact for its business customers. Any
statements contained in this communication that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as “believes,” “anticipates,” “plans,” “expects,”
“will,” “intends,” “potential,” “possible,” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including but not limited to,
risks relating to market acceptance of its products. In addition,
Inogen's business is subject to numerous additional risks and
uncertainties, including, among others, risks relating to market
acceptance of its products; competition; its sales, marketing and
distribution capabilities; its planned sales, marketing, and
research and development activities; interruptions or delays in the
supply of components or materials for, or manufacturing of, its
products; seasonal variations; unanticipated increases in costs or
expenses; and risks associated with international operations.
Information on these and additional risks, uncertainties, and other
information affecting Inogen’s business operating results are
contained in its Annual Report on Form 10-K for the period ended
December 31, 2022, and in its other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. Inogen disclaims any obligation to update these
forward-looking statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230807703310/en/
Agnes Lee ir@inogen.net
Inogen (NASDAQ:INGN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024